Extended treatment of cancer-associated thrombosis

Venous thromboembolism (VTE) is a growing concern in patients with cancer. Current guidelines recommend that cancer patients with VTE should receive anticoagulation for at least 3-6 months. However, the question as to whether anticoagulants should be continued after 3 to 6 months of treatment remains open. In presence of an active malignancy, physicians should weigh the benefits and burdens of ongoing anticoagulation taking into account the clinical status, patient expectations, and the risk of bleeding. As the length of time from the index event increases, the available evidence is not conclusive. The most critical unresolved issues include the decision to continue or discontinue anticoagulation and the selection of the most appropriate anticoagulant agent. On this background, our article provides an overview of the available studies focusing on extended (i.e., >6 months) anticoagulation treatment in cancer-associated thrombosis, with the ultimate goal of refining real-world clinical decision-making in this patient population.